• Paroxetine Mesylate: Research Workflows

  2026-08-19

  Paroxetine Mesylate combines high-affinity SERT activity with measurable CYP2D6, GRK2, MET, and ERBB3-related pharmacology, making it useful for integrated neuropharmacology and oncology studies. This guide converts that polypharmacology into practical cell-based workflows, assay controls, and troubleshooting decisions.

• LDN-193189: From BMP Mechanism to Translation

  2026-08-19

  LDN-193189 is a selective BMP type I receptor inhibitor that enables researchers to connect ALK2 and ALK3 signaling with Smad activity, epithelial barrier phenotypes, and translational disease models. This thought-leadership guide outlines how to deploy the compound rigorously, interpret cross-domain evidence, and distinguish validated biology from forward-looking hypotheses.

• How Oxidative Stress Activates ATM: Structural Insights

  2026-08-18

  Howes, Perisic, and Williams used cryo-EM and biochemical analysis to define how hydrogen peroxide activates the DNA damage kinase ATM. Their structure links a redox-sensitive disulfide bridge to dimer rotation, release of an autoinhibitory region, kinase-domain remodeling, and productive p53 substrate binding.

• TAI-1 Hec1 Inhibitor: Workflows & Applications

  2026-08-18

  TAI-1 gives cancer researchers a practical route to connect Hec1–Nek2 disruption with mitotic failure, proliferation loss, and apoptotic cell death induction. This guide combines dose-response, chromosome-imaging, combination-treatment, and replication-stress assays with troubleshooting strategies for triple negative breast cancer research and liver cancer research.

• Chenodeoxycholic Acid: From FXR Signal to Assay Design

  2026-08-17

  Chenodeoxycholic Acid (CDCA) is more than an FXR agonist: it can serve as a mechanistic probe linking bile acid metabolism to transcriptional and injury-response assays. This guide translates recent FXR–KLF11 findings into a rigorous framework for experimental design, controls, and interpretation.

• Central Control of Opioid Mechanical Hypersensitivity

  2026-08-17

  Yin et al. identify a brain-to-spinal opioid pathway linking MOR-expressing neurons in the lateral parabrachial nucleus, dynorphin neurons in the hypothalamus, and KOR-expressing GABAergic neurons in the spinal dorsal horn. Their findings distinguish central control of mechanical opioid-induced hypersensitivity and tolerance from better-established thermal mechanisms and provide a circuit framework for receptor- and pathway-level experiments.

• ETS1–SENP2 Axis in Bronchopulmonary Dysplasia

  2026-08-16

  A 2026 study identifies ETS1 as a transcriptional regulator that protects against hyperoxia-associated bronchopulmonary dysplasia by coordinating SENP2-dependent deSUMOylation, HSPA8 binding, and FUNDC1 degradation. The findings connect mitochondrial quality control with alveolar injury and suggest that excessive mitophagy, rather than autophagy activation in general, may be a context-dependent therapeutic target.

• Plant Cell Lysis Buffer for WB and IP: MAPK10 Assays

  2026-08-15

  Build cleaner Western blotting, immunoprecipitation, and co-IP workflows from plant, animal, fungal, or bacterial samples with a non-denaturing extraction system. This guide translates MAPK10–KRT16 pathway findings into practical sample-preparation, assay-selection, and troubleshooting decisions.

• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-08-14

  The reference study identifies a hormone–chromatin–chemokine pathway in which trophoblast-derived hCG increases EZH2-associated H3K27me3 at the CXCL10 promoter in human decidual stromal cells. This mechanism links placental signaling to reduced CD8 T-cell recruitment and provides a useful framework for studying epigenetic control of immune adaptation at the maternal–fetal interface.

• T7 RNA Polymerase for Precise In Vitro RNA Synthesis

  2026-08-14

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes DNA templates carrying a T7 promoter. Its defined promoter recognition supports in vitro RNA synthesis for research workflows, including RNA vaccine production, antisense RNA, and RNAi studies.

• Bestatin (Ubenimex): Mechanism & Research Guide

  2026-08-13

  Bestatin, also called Ubenimex, is a research aminopeptidase inhibitor with reported activity against cytosol aminopeptidase, aminopeptidase N, zinc aminopeptidase, and aminopeptidase B. Its effects are assay-dependent: a peer-reviewed fibrin-matrix model found enhanced endothelial tube formation, so Bestatin should not be labeled universally anti-angiogenic.

• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-13

  The reference study develops a rationally optimized human GBA1 mRNA platform that improves glucocerebrosidase expression, durability, and lysosomal delivery. In cellular and mouse experiments, the mRNA–lipid nanoparticle system restored disease-relevant enzyme function, supporting further investigation of mRNA therapy as an alternative or complement to enzyme replacement and substrate reduction strategies.

• PNU 74654: Designing Better Wnt Assays

  2026-08-12

  PNU 74654 is a Wnt signaling pathway inhibitor for testing how β-catenin-dependent signals shape cell fate. This guide focuses on causal assay design, controls, and responsible interpretation across cancer research, stem cell research, and muscle biology.

• Praeruptorin A, DMT1, and Ferroptosis in DIC

  2026-08-12

  This study used a ferrous-ion probe to screen herbal small molecules and identified Praeruptorin A as an intervention candidate for doxorubicin-induced cardiomyopathy. The evidence connects Praeruptorin A with reduced DMT1 expression, lower cardiomyocyte Fe2+ overload, suppressed ferroptosis, improved cardiac function, and retained doxorubicin antitumor activity.

• ABT-263 (Navitoclax) Apoptosis Workflow

  2026-08-11

  Build more informative apoptosis assays with ABT-263 (Navitoclax), from dose-response screening to mitochondrial mechanism validation. This workflow also translates a senescence-selective study into practical controls without overstating what Navitoclax has demonstrated in non-cancer tissues.

8625 records 9/575 page Previous Next First page 上5页 678910 下5页 Last page